• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

DiaMedica Therapeutics Inc. - Common Stock (NQ:DMAC)

8.720 +0.090 (+1.04%)
Delayed Quote Updated: 4:00 PM EDT, Oct 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 110,030
Open 8.550
Bid (Size) 8.300 (200)
Ask (Size) 8.950 (100)
Prev. Close 8.630
Today's Range 8.290 - 8.790
52wk Range 5.245 - 10.42
Shares Outstanding 37,953,711
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
DiaMedica Therapeutics Announces Enrollment of 200th Patient in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
October 22, 2026
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar
October 19, 2026
From DiaMedica Therapeutics Inc.
Via Business Wire

Performance

52-Week Range 16.3% below 52-week high
8.720
5.2552W Low 10.4252W High
1 Week 2.6% below 1-week high
7.601W Low 8.951W High

DiaMedica Therapeutics Inc. - Common Stock (DMAC) traded between $5.25 and $10.42 over the past 52 weeks and last traded at $8.72, 16.3% below its 52-week high. Over the past week it ranged between $7.60 and $8.95.

Past 12 Months
+10.8%
+15.3%
+29.5%
+37.8%
+10.0%
+29.0%
1W +$0.85
1M +$1.16
3M +$1.99
6M +$2.39
YTD +$0.79
1Y +$1.96

DMAC was +29.0% over the past year, +37.8% over six months, +10.0% year to date, +10.8% in the last week.

12 Months vs Market
DMAC
+29.0%
DIA
+11.6%
SPY
+13.1%
QQQ
+15.4%
IWM
+11.9%

Over the past 12 months DMAC returned +29.0% versus DIA (Dow) +11.6%, SPY (S&P 500) +13.1%, QQQ (Nasdaq 100) +15.4% and IWM (Russell 2000) +11.9%.

Volume & Liquidity 0.61× 3-mo avg
Today 110,030 3-mo avg 180.4K
1W
142.0K
1M
222.2K
3M
180.4K
6M
190.8K
YTD
199.4K
1Y
246.1K

DMAC most recently traded 110,030 shares against a 3-month average daily volume of 180.4K.

More News

Read More
News headline image
DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction Featuring Early Phase 2 FGR Results
September 30, 2026
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics to Participate in Upcoming September Investor Conferences
September 02, 2026
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics (NASDAQ:DMAC) Posts Wider Q1 Loss but Clinical Catalysts Fuel Stock Resilience ↗
May 06, 2026
Via Chartmill
News headline image
DiaMedica (DMAC) Q2 2026 Earnings Call Transcript ↗
August 17, 2026
Via The Motley Fool
Topics Earnings
News headline image
DiaMedica Therapeutics Q2 Earnings Call Highlights ↗
August 11, 2026
Via MarketBeat
Topics Earnings
News headline image
DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
August 10, 2026
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026
August 04, 2026
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 17, 2026
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction
June 23, 2026
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program
June 16, 2026
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica (DMAC) Q4 2025 Earnings Transcript ↗
June 01, 2026
Via The Motley Fool
Topics Intellectual Property
News headline image
DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026
May 27, 2026
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
May 20, 2026
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
May 12, 2026
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica (DMAC) Q1 2026 Earnings Transcript ↗
May 08, 2026
Via The Motley Fool
Topics Death
News headline image
DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
May 06, 2026
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026
April 30, 2026
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
RedChip's Biotech Virtual Investor Conference Replays Now Available
April 21, 2026
Via ACCESS Newswire
News headline image
RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms
April 07, 2026
Via ACCESS Newswire
News headline image
DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights
March 30, 2026
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
Top Wall Street Forecasters Revamp DiaMedica Therapeutics Expectations Ahead Of Q4 Earnings ↗
March 30, 2026
Via Benzinga
News headline image
DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026
March 23, 2026
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia
March 05, 2026
From DiaMedica Therapeutics Inc
Via Business Wire

Frequently Asked Questions

Is DiaMedica Therapeutics Inc. - Common Stock publicly traded?
Yes, DiaMedica Therapeutics Inc. - Common Stock is publicly traded.
What exchange does DiaMedica Therapeutics Inc. - Common Stock trade on?
DiaMedica Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for DiaMedica Therapeutics Inc. - Common Stock?
The ticker symbol for DiaMedica Therapeutics Inc. - Common Stock is DMAC on the Nasdaq Stock Market
What is the current price of DiaMedica Therapeutics Inc. - Common Stock?
The current price of DiaMedica Therapeutics Inc. - Common Stock is 8.720
When was DiaMedica Therapeutics Inc. - Common Stock last traded?
The last trade of DiaMedica Therapeutics Inc. - Common Stock was at 10/23/26 04:00 PM ET
What is the market capitalization of DiaMedica Therapeutics Inc. - Common Stock?
The market capitalization of DiaMedica Therapeutics Inc. - Common Stock is 330.96M
How many shares of DiaMedica Therapeutics Inc. - Common Stock are outstanding?
DiaMedica Therapeutics Inc. - Common Stock has 331M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap